ENDOSURE Test Research
Clinical decision support for an earlier endometriosis diagnosis
ENDOSURE is an accurate yet non-invasive diagnostic test for endometriosis. The ENDOSURE test uses an electroviscerography system (EVG), an analytical instrument that collects GastroIntestinal Myoelectrical Activity (GIMA) signals from the abdomen through dry electrodes. Very similar to an electrocardiogram/ECG it’s easy to perform and provides simple, objective data that provides decision support when endometriosis is suspected. Authorized for sale by Health Canada (MDALL 107153), ENDOSURE test, by 3CPM, is a Class-2 medical device that is non-invasive and non-active.
Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis
Validation of New GIMA Biomarker Signature of Endometriosis
Gastrointestinal Myoelectrical Activity (GIMA) Biomarker Accurately Determines Presence of Absence of Endometriosis
Presented by: Maria Porcellato, BSP, ACPR, CFCPH
Confirming research for the ENDOSURE test was presented as an Abstract in Zagreb, Croatia at the 2025 RRM Congress. This research was significant, as the 340 patient set validated the ENDOSURE test used in a real world experience. Key findings include a sensitivity of 95%, a specificity of 86%, and a diagnostic accuracy of 92%.
Defining the Role of the Gastrointestinal Myoelectrical Activity (GIMA) Biomarker in the Diagnosis of Endometriosis1
Authors: P Tanos, F Donders, A Massaro, S Philippe, S Kampala’s with research from the Centre Hospitalier Universitaire (CHU) Brugmann, Brussels, Belgium
Findings: CHU Bruggman, Brussels, validated GIMA v. MRI (35 patients), TV-US (45 patients) and laparoscopy (12 patients) using #Enzian classification. Sensitivity 100%, specificity of 5% (no benign cohort), diagnostic accuracy of 96% in detecting both deep and superficial endometriosis (preliminary data, May 2025). Notably, GIMA biomarkers identified superficial endometriosis in cases missed by conventional imaging. Additionally, 60% of patients preferred ENDOSURE over TV-US.
2025 Congress Oral Abstract Presentation
Non-Invasive Electroviscerography for the Diagnosis of Endometriosis: A Prospective Pilot Study
Authors: Marina P Andres, MD , Ana Clara P Servidoni , Ana Luiza B Luduwig , Lara L Passos , Mariana M Brunoro and Mauricio S Abrao, MD
Findings: Compared to laparoscopy (n=13) of 43 women, EVG showed sensitivity 100%, specificity 0%, accuracy 92.31%. Compared to TVUS (n=30) EVG showed sensitivity 81.28%, specificity 26.32%, accuracy 46.67%
1 Tanos P, Donders F, Massaro A, Philippe S, Karampelas S. Defining the role of the gastrointestinal myoelectrical activity (GIMA) biomarker in the diagnosis of endometriosis. J Minim Invasive Gynecol. 2025;32(11)(suppl):S23. doi:10.1016/j.jmig.2025.09.027.
Important: the studies in this section have been presented at AAGL & IIRRM Congresses but have not yet been published or peer reviewed.
Published Research
Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis
Objective: demonstrate the GIMA biomarker is unique to endometriosis, allowing accurate, rapid & non-invasive diagnosis, or exclusion of endometriosis. n=154
Intervention: Electroviscerography system (EVG) recorded GIMA biomarkers from 3 abdominal electrodes for 30 minutes post-waterload.
Results: Subjects with endometriosis demonstrated unique GIMA biomarker pattern, characteristic of the disease. Subjects without endometriosis were negative for the biomarker. GIMA biomarker threshold scoring demonstrated 99.87% accuracy, 95% selectivity, 96% specificity for patients <36 years (98.5%,91%, 95% respectively, patients 36 yr+). In validation cohort, GIMA biomarker threshold scoring detected 47 patients who were positive and 2 patients that were negative for endometriosis, subsequently confirmed surgically. Hormonal therapy, surgical stage, and pain score did not affect diagnostic accuracy.
Conclusions: EVG with GIMA biomarker detection distinguished participants with and without endometriosis based upon endometriosis-specific GIMA biomarker threshold scoring. Confirmatory studies have been conducted at research institutions throughout the world with interim results already presented.
- Noar M, Mathias J, Kolatkar A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. J Clin Med. 2024;13(10):2866. Published 2024 May 13. doi:10.3390/jcm13102866
Published Research
Validation of New GIMA Biomarker Signature of Endometriosis – Interim Data: Research Article
The validation of novel GIMA (Gastrointestinal Myoelectrical Activity) biomarker signature of endometriosis with interim data from a multicenter, prospective blinded trial aims to validate the diagnostic accuracy of the GIMA biomarker. Results:
-
GIMA biomarkers detected via electroviscerography (EVG) demonstrated:
-
96% sensitivity
-
96% specificity
-
100% C-statistic
- Hormonal therapy, disease stage, age nor pain score affected diagnostic accuracy
-
Mark Noar, John Mathias, Ajit Kolatkar. Validation of New GIMA Biomarker Signature of Endometriosis – Interim Data: Research Article. Advance. August 26, 2024.
DOI: 10.22541/au.172469630.08159498/v1
Published Research
AI-Derived Threshold Score of Intraabdominal Myoelectrical Activity Predicts Presence and Stage of Endometriosis with 100% Accuracy
November 2022, Journal of Minimally Invasive Gynecology
Endometriosis-specific abnormalities of GMA post-WLST predicts surgically detected endometriosis w/100% accuracy. AI GMA-derived threshold detects endometriosis with 100% sensitivity and specificity. Hormonal suppression, symptoms and surgical grade of endometriosis did not affect test accuracy. Variations in Ai-derived threshold scores may predict surgical stage of endometriosis. EVG represents an ideal test for the detection and screening of endometriosis.
AI-Derived Threshold Score of Intraabdominal Myoelectrical Activity Predicts Presence and Stage of Endometriosis with 100% Accuracy, Noar, M., Journal of Minimally Invasive Gynecology, Volume 29, Issue 11, S4 – S5. DOI: 10.1016/j.jmig.2022.09.026
Published Research
Relation of endometriosis & neuromuscular disease of the gastrointestinal tract: new insights
July 1998, Reproductive Endocrinology
Published in 1998, this study unveiled intriguing connections between endometriosis and neuromuscular diseases of the gastrointestinal tract, which initiate GIMA biomarker research fellow gastroenterologist, Dr. Mark Noar. The study employed a combination of histological analysis, immunohistochemistry, and microbiome sequencing. Findings were statistically significant (p < 0.01) across multiple cohorts totaling over 500 patients. Key findings included evidence of shared pathophysiology, neurological involvement, hormonal influence of estrogen receptors and microbiome alternations.
Mathias JR, Franklin R, Quast DC, Fraga N, Loftin CA, Yates L, Harrison V. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. Fertil Steril. 1998 Jul;70(1):81-8. DOI: 10.1016/s0015-0282(98)00096-x.